Horizon Teprotumumab's US Advisory Cmte. Likely To Focus On Labeling, Not Approval, Questions
FDA seems poised to approve the drug for the orphan eye disease called TED, but remains concerned about labeling for some adverse events.
FDA seems poised to approve the drug for the orphan eye disease called TED, but remains concerned about labeling for some adverse events.